South America Alpha Glucosidase Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The South America alpha glucosidase inhibitors market size was valued at USD 0.21 billion in 2025 and is estimated to grow from USD 0.22 billion in 2026 to reach USD 0.24 billion by 2031, at a CAGR of 2.17% during the forecast period (2026-2031). This report is segmented by Drug Type (Acarbose, Miglitol, Voglibose, Combination Products), Indication (Type-1 Diabetes, Type-2 Diabetes Population), Distribution Channel (Retail, Hospital, Online Pharmacies), and Geography (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America). The Market Forecasts are Provided in Terms of Value (USD).

South America Alpha Glucosidase Inhibitors Market Trends and Insights

Rising Type-2 Diabetes Burden

Type 2 diabetes provides a broad patient base for the South America alpha-glucosidase inhibitors market. The International Diabetes Federation estimated that 35.4 million adults in South and Central America lived with diabetes in 2024, generating USD 81 billion in diabetes-related healthcare expenditure. It also reported that 30.4% of people with diabetes, or more than 10.7 million individuals, were undiagnosed. Colombia had 3.0 million adults with diabetes in 2024, with 16.2% of cases undiagnosed. The regional diabetes population is projected to reach 52 million by 2050, supporting demand for postprandial glucose-control therapies.

Oral Therapy Access and Lower-Cost Generic Treatment

Oral medications remain important in Type 2 diabetes management, as injectable treatments can be unaffordable for patients without private coverage. Clinical guidelines across Latin America position established oral therapies as core treatments, while newer drugs primarily target patients with cardiovascular or kidney risks. Alpha-glucosidase inhibitors retain a role when patients cannot tolerate metformin or require postprandial glucose control. Generic acarbose and miglitol improve affordability, while Brazil’s pricing framework requires generics to be priced at least 35% below reference products. However, increasing generic competition may pressure unit prices.

Competition from Newer Diabetes Therapies

Competition from metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors is a key restraint on the South America alpha-glucosidase inhibitors market. In May 2026, Brazil’s National Health Surveillance Agency registered Eurofarma’s first generic fixed-dose combination of dapagliflozin and metformin hydrochloride, expanding access to lower-cost oral treatment options for type 2 diabetes. Clinical guidelines prioritize SGLT2 inhibitors for patients with cardiovascular disease, heart failure, or diabetic kidney disease, reducing the target patient pool for alpha-glucosidase inhibitors. Competition is strongest in private insurance formularies and urban specialist settings, although the class remains relevant where newer therapies are unsuitable, unavailable, or unaffordable.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Private Diabetes-Care Networks
• Public Formulary Gaps and Established Prescribing Patterns
• Gastrointestinal Tolerability and Uneven Access

Segment Analysis

Acarbose held 59.80% of the South America alpha-glucosidase inhibitors market in 2025. Its leadership reflects Bayer’s Glucobay presence as a reference product across South American regulatory systems and the availability of generic alternatives. Familiarity among endocrinologists and general practitioners, particularly in Brazil’s interior states and Argentina’s provincial markets, continues to support prescribing. Generic supply from Brazilian and Indian manufacturers improves access for price-sensitive patients, while voglibose and combination products maintain limited roles.

Miglitol is forecast to grow at a 6.89% CAGR from 2026 to 2031, making it the fastest-growing drug type. Its absorption profile supports selected patients with early-stage type 2 diabetes and high post-meal glucose levels, particularly when renal conditions limit metformin use. Prescribers in Brazil and Colombia are becoming more familiar with its use, although careful patient selection remains necessary because glucagon cannot be used to manage associated hypoglycemia. Local generic availability can further support segment growth.

Complete Report Scope:

• By Drug Type
  • Acarbose
  • Miglitol
  • Voglibose
  • Combination Products Containing an Alpha Glucosidase Inhibitor
• By Indication
  • Type-1 Diabetes Population
  • Type-2 Diabetes Population
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• By Geography
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America

List of Companies Covered in this Report:

• Aché Laboratórios Farmacêuticos S.A.
• Bayer
• Biolab Sanus Farmacêutica Ltda.
• EMS S/A
• Eurofarma Laboratórios S.A.
• Glenmark Pharmaceuticals
• Hypera S.A.
• Laboratório Teuto Brasileiro S.A.
• Laboratorios Bagó S.A.
• Laboratorios Roemmers S.A.
• Merck
• Merck
• Pfizer
• Prati-Donaduzzi & Cia Ltda.
• Siegfried Holding AG
• Sun Pharmaceuticals Industries
• Takeda Pharmaceuticals
• Torrent Pharmaceuticals Limited
• União Química Farmacêutica Nacional S/A
• Unichem Laboratories Limited
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support